Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Bombay HC Quashes MPDA Detention For 99-Day Delay; Calls Preventive Custody ‘Punishment Without Trial’
Uttar Pradesh News: Deputy CM Keshav Prasad Maurya Hears Hundreds At Janata Darshan, Orders Time-Bound Redressal Of Grievances
Veteran Socialist Leader Dr Baba Adhav Passes Away At 95 In Pune
Uttar Pradesh Govt Promotes 4 IAS Officers To Principal Secretary Rank; 20 From 2010 Batch Cleared For Secretary Post
